OncoFrontier

Frontier cancer treatments most patients don't know exist | AI and Tech in Oncology. Radiopharmaceuticals · Bispecific Antibodies · ADCs | By @CancerFax

[OncoFrontier @TheOncoFrontier]

This lands alongside Oracle's new AI-enabled oncology EHR and a proposed MSK–Qatar AI cancer-care partnership. AI is increasingly showing up in oncology's infrastructure layer, not just in headline drug deals.

Where should AI-accessible modelling tools focus first?

#OncologyAI

[OncoFrontier @TheOncoFrontier]

A tumour, simulated inside a computer, built in minutes instead of months. Researchers at the Barcelona Supercomputing Center just made that possible.
🧵 @CancerFax

#AIinOncology #DigitalTwin

[OncoFrontier @TheOncoFrontier]

Important caveat: a faster model isn't automatically a correct one. Every digital twin still needs expert review of its biological assumptions and validation against real patient or experimental data before it means anything clinically.

#PrecisionMedicine

[OncoFrontier @TheOncoFrontier]

Lands alongside this month's AACR Cancer Progress Report highlighting AI's expanding role across research, screening, and trial design, plus Insilico Medicine's AI-designed drug reaching first-in-human data at ESMO.

Where should AI target discovery focus next?

#CancerResearch

[OncoFrontier @TheOncoFrontier]

A single gene can be read out in different ways. Cancer sometimes reads it differently than healthy cells do, and that difference just became a billion-dollar cancer target.

🧵 @CancerFax

#AIinOncology #DrugDiscovery

[OncoFrontier @TheOncoFrontier]

Important context: this is target discovery and validation, not a treatment that has reached a patient. Turning a computational target into an approved drug is still a multi-year road with plenty of points where things can fail.

#OncologyAI

[OncoFrontier @TheOncoFrontier]

Nothing alters treatment today. It shows where capital and pharma R&D are betting: compressing drug development's slowest parts. The validation bar for patient-touched items remains.

Where does AI gain clinical trust first in oncology?

#PrecisionMedicine

[OncoFrontier @TheOncoFrontier]

AI just had a big week in oncology. $25M raised. A major pharma partnership signed. A 37,000-agent AI research system in the headlines again. Here's what actually happened and what it doesn't mean yet.

🧵 @cancerfax

#AIinOncology #CancerResearch

[OncoFrontier @TheOncoFrontier]

A 37,000-agent "virtual biotech" continues to draw attention for AI-generated hypotheses, including one involving the B7-H3 cancer target. Interesting? Yes. Clinical proof? Not yet. Hypothesis generation is step one of many.

#OncologyAI

[OncoFrontier @TheOncoFrontier]

Reality check worth remembering: no AI-designed cancer drug has reached regulatory approval yet. Promising predictions are still a long way from clinical proof.

Do simulation-based models like this feel more promising to you than single-outcome prediction tools?

#AIinOncology

[OncoFrontier @TheOncoFrontier]

A simulated tumour, fighting a simulated immune system, inside a computer, before any patient is involved. Big Picture Bio just raised 2.55 million euros to build exactly that.

🧵 @CancerFax

#AIinOncology #DrugDiscovery

[OncoFrontier @TheOncoFrontier]

Reported result: 12 of 14 pre-ASCO predictions were accurate. Worth watching, but these are company-reported figures that still need independent publication and prospective validation.

#CancerResearch